Loading...
•
Dec 31, 2025
Scynexis Q4 2025 Earnings Report
Key Takeaways
SCYNEXIS strengthened its financial position in Q4 2025 by receiving $24.8 million from GSK, extending its cash runway into 2028. While the company focused on advancing its second-generation fungerp SCY-247, total cash reserves decreased year-over-year to $56.3 million.
Received $24.8 million in non-refundable payments from GSK during the fourth quarter.
Cash runway extended for more than two years, providing stability for clinical development.
Advancing SCY-247 with Phase 1 intravenous formulation data expected later in 2026.
Full-year revenue was significantly impacted by a $17.2 million cumulative catch-up related to the GSK license agreement.
Revenue by Segment
Forward Guidance
SCYNEXIS is focused on clinical milestones for SCY-247 and leveraging its extended cash runway to enhance shareholder value through 2026.
Positive Outlook
- Cash runway extended for more than two years.
- Phase 1 data for SCY-247 IV formulation expected later this year.
- Receipt of $24.8 million from GSK in Q4 2025.
- Reduction in R&D expenses by 15.6% due to CMC and salary efficiencies.
- Strong balance sheet to explore value-enhancing opportunities.
Challenges Ahead
- Total cash and investments decreased from $75.1M to $56.3M year-over-year.
- Other income decreased significantly due to warrant liability fair value adjustments.
- Product revenue is currently tied to recall-related estimates rather than new sales.
- Preclinical and clinical expenses saw slight increases despite overall R&D savings.
Loading...
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...